BSX — Boston Scientific Corporation

Boston Scientific Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $5.203 billion, representing 11.6% reported growth year-over-year, with organic revenue growth of 9.4%.
• Adjusted EPS: $0.80, a 6% increase, achieving the high end of guidance ($0.78 to $0.80).
• Adjusted Operating Margin: 28.8%, with a GAAP operating margin of 21.2%.
• Free Cash Flow: $170 million for the quarter; projected full-year free cash flow of approximately $4 billion.
• Cash on Hand: $1.453 billion, with a gross debt leverage ratio of 1.8x.

2. Strategic Updates and Business Highlights

• U.S. Growth: 11% organic growth, with double-digit growth in five out of eight business units.
• International Growth: Asia Pacific saw strong performance with 12% growth, while EMEA grew only 1% due to the discontinuation of certain products.
• Product Highlights: Strong performance from FARAPULSE, WATCHMAN, and Neuromodulation products. The company received PMDA approval for a coronary drug-coated balloon in Japan.
• Acquisitions: Closed the acquisition of Valencia Technologies and expects the Penumbra acquisition to close in the second half of 2026.

3. Forward Guidance and Outlook

• Q2 2026 Guidance: Organic growth expected to be 5% to 7%, with adjusted EPS guidance of $0.82 to $0.84.
• Full-Year 2026 Guidance: Reduced organic growth forecast to 6.5% to 8%, with adjusted EPS expected to be between $3.34 and $3.41, reflecting 9% to 11% growth.
• Long-Term Outlook: Confidence in achieving double-digit EPS growth and margin improvement over the long-range plan (LRP).

4. Bad News, Challenges, or Points of Concern

• Guidance Reduction: The company lowered its growth expectations due to unanticipated headwinds, particularly in the areas of Electrophysiology (EP), WATCHMAN, and Urology.
• WATCHMAN Volume Pressure: Notable deceleration in stand-alone WATCHMAN procedures, attributed to evolving practice patterns and increased competition.
• Urology Performance: Urology sales grew only 1%, falling short of expectations, primarily due to challenges in the stone management and neuromodulation segments.
• Competitive Pressures: Increased competition in the EP market, particularly from Medtronic, J&J, and Abbott, leading to anticipated share erosion.

5. Notable Q&A Insights

• Market Dynamics: Management acknowledged unexpected declines in WATCHMAN volumes starting in February, impacting guidance. They emphasized the need for increased commercial focus and marketing investments to address these challenges.
• Urology Strategy: The company is implementing plans to stabilize and improve the Urology business, including hiring and training new sales representatives.
• Future Product Launches: Confidence in upcoming product launches, particularly in EP and WATCHMAN, with expectations for improved growth in 2027.
• Acquisition Strategy: Management expressed commitment to the Penumbra acquisition despite current market conditions, indicating confidence in the strategic fit and growth potential.

Overall, while Boston Scientific reported solid Q1 results, the company faces significant challenges that have led to a cautious outlook for the remainder of 2026.